LTS LOHMANN Therapie-Systeme AG

LTS LOHMANN Therapie-Systeme AG, a Germany-based pharmaceutical technology company, announced it has completed its acquisition of Renaissance Lakewood , a U.S.-based contract development and manufacturing organization specializing in nasal sprays and sterile dosage forms. The transaction, first announced in October 2025 , has received regulatory approvals, according to the company. Renaissance’s operations and 500 employees will now be integrated into LTS’ global network, which includes sites in Germany, the United States, and Israel. LTS said the acquisition broadens its contract development and manufacturing capabilities and strengthens its position as a global provider of innovative drug delivery technologies. Following the closing, Renaissance will operate as a new division named LTS Nasal & Sterile Drug Products, led by Serge Maltais, former president and CEO of Renaissance. “With the closing of this transaction, we are proud to welcome Renaissance Lakewood to the LTS family,” LTS CEO Bas van Buijtenen said in a statement. “By combining strengths, we can create more impact — for our partners, our patients, and the broader healthcare community. Together, our expanded capabilities and shared commitment to innovation will enable us to set new standards in drug delivery and CDMO services worldwide.” This piece was created with the assistance of generative AI tools and was edited by our content team for clarity and accuracy.

LTS Lohmann Therapie-Systeme AG, a Germany-based pharmaceutical technology company, announced it will acquire Renaissance Lakewood , a U.S.-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. Upon completion, Renaissance’s Lakewood, New Jersey facilities will join LTS’s global manufacturing network, which includes sites in Andernach, Germany; West Caldwell, New Jersey; St. Paul, Minnesota; and Netanya, Israel. The acquisition will reportedly expand LTS’s CDMO capabilities and strengthen its position in drug delivery innovation, according to the company. Renaissance, founded in 1979 and currently owned by RoundTable Healthcare Partners, operates multiple suites for unit-dose, bi-dose, and multi-dose nasal sprays, as well as small-volume parenteral fill-finish vials. Its R&D laboratories reportedly support formulation development and spray characterization. Renaissance employs about 500 people. The transaction is expected to close before the end of November 2025, subject to regulatory approvals.

LAKE FOREST, Ill., Oct. 13, 2025 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company Renaissance Lakewood ("Renaissance") has entered into a definitive agreement to be acquired by LTS LOHMANN Therapie-Systeme AG ("LTS"). LTS is a pharmaceutical technology company developing and manufacturing innovative drug delivery systems and is located in Andernach, Germany. Terms of the transaction were not disclosed. Renaissance is a premier contract development and manufacturing organization ("CDMO") focused on nasal and injectable pharmaceutical products, including unit-dose, bi-dose, and multi-dose nasal sprays as well as small-volume parenteral fill-finish vials. Renaissance was founded by RoundTable through the acquisition of two leading CDMOs, Confab Laboratories in 2010 and DPT Laboratories in 2012. Following the 2016 divestiture of its topicals division to Mylan N.V., the company has focused on advancing its intranasal and injectable dosage platforms. Through significant investments in leadership and talent, research & development, and state-of-the-art infrastructure, Renaissance has evolved into a leading, fully integrated CDMO and serves as a partner to both established and emerging pharmaceutical and biotech customers. Pierre Frechette, Managing Partner of RoundTable and Chairman of Renaissance, commented, "On behalf of RoundTable, I would like to thank our exceptional management team and talented employees of Renaissance for creating a high-quality, differentiated business. We believe LTS will be a strong long-term partner to support the business moving forward." Serge Maltais, President & CEO of Renaissance added, "Renaissance has benefited tremendously from RoundTable's support and guidance. Together, we've grown and transformed the company into one of the industry leaders that it is today. We thank RoundTable and now look forward to an exciting future as part of LTS." This transaction is expected to close in November 2025, subject to regulatory approvals. Sidley Austin LLP acted as exclusive legal advisor to Renaissance and RoundTable in this transaction. About RoundTable Healthcare Partners RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs, and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable has raised $4.25 billion in committed capital, including six equity funds totaling $3.65 billion and three subordinated debt funds totaling $600 million. More information about RoundTable Healthcare Partners can be found at . SOURCE RoundTable Healthcare Partners WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED